98%
921
2 minutes
20
Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease that causes joint inflammation and destruction with an unknown origin. Our study aims to elucidate the molecular mechanism behind HIF1α overexpression in RA. Dysregulated miRNA expressions are known to influence gene behavior, thereby enhancing cell proliferation, inflammation, and resistance to apoptosis, contributing to RA development. Our earlier finding indicated that exogenous miRNA similar to miR-4693-5p may modulate RA-related targets. However, the specific role of miR-4693-5p and its targets in RA remain unexplored. In this study, we found that miR-4693-5p was significantly reduced in PBMCs of RA patients, with evidence suggesting it targets the 3' UTR of HIF1α, thereby potentially contributing to its overexpression in RA. In vitro overexpression of miR-4693-5p leads to the knockdown of HIF1α, resulting in inhibited expression of Survivin to disrupt apoptosis resistance, inflammation suppression, and a reduction in the total cellular ROS response in SW982 and RAFLS cells. The results were validated using the CIA Rat model. In conclusion, this study provides a crucial foundation for understanding the functional role of miR-4693-5p. These findings improve our understanding and provide novel insights into the molecular mechanisms underlying RA pathogenesis.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11053697 | PMC |
http://dx.doi.org/10.3390/ncrna10020022 | DOI Listing |
Biochim Biophys Acta Mol Cell Biol Lipids
September 2025
Laboratory of Biochemistry, University of Crete Medical School and Gene Regulation and Genomics group, Institute of Molecular Biology and Biotechnology, Foundation for Research and Technology of Hellas, Heraklion, Crete, Greece. Electronic address:
Rheumatoid arthritis (RA) is associated with increased cardiovascular disease (CVD) risk, partly attributed to altered lipid metabolism. Apolipoprotein C-III (apoC-III), a key regulator of triglyceride-rich lipoproteins in the plasma, has been implicated in both dyslipidemia and inflammation. In this study, we investigated the role of hypertriglyceridemia in RA using a transgenic mouse model overexpressing the human apoC-III gene (apoC-III Tg).
View Article and Find Full Text PDFJ Ethnopharmacol
September 2025
School of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou 310053, China. Electronic address:
Ethnopharmacological Relevance: Chronic inflammatory pain represents a significant global health burden, seriously affecting the patient's quality of life. Jin-Tian-Ge Capsules (JTG), a substitute for natural tiger bone, has been approved in China for the treatment of osteoporosis, osteoarthritis and rheumatoid arthritis. Clinical observations show that JTG can mitigate chronic pain associated with the above bone-related diseases.
View Article and Find Full Text PDFEur J Gastroenterol Hepatol
September 2025
Department of Gastroenterology, First Affiliated Hospital of Shantou University Medical College, Shantou.
Background: Crohn's disease (CD) and rheumatoid arthritis (RA) are autoimmune diseases. CD is known to be closely associated with RA. However, the mechanisms underlying these relationships remain unclear.
View Article and Find Full Text PDFBraz Oral Res
September 2025
Universidade de Ribeirão Preto - Unaerp, Graduate Program in Dentistry, Ribeirão Preto, SP, Brazil.
The aim of this study was to assess the prevalence of temporomandibular disorder (TMD) and associated factors in an adult population in southern Brazil. The population-based sample (n = 4.65) included participants from Passo Fundo, a town in southern Brazil.
View Article and Find Full Text PDFRev Bras Enferm
September 2025
Universidade Federal de Mato Grosso do Sul. Campo Grande, Mato Grosso do Sul, Brazil.
Objectives: to analyze the relationship between self-care and pharmacotherapy complexity in individuals with rheumatoid arthritis.
Methods: this cross-sectional study was conducted at a teaching hospital in the Central-West region of Brazil from October to December 2023. Individuals with rheumatoid arthritis undergoing treatment for at least three months were included.